In total, although ATRIP LoF variants seem to be relatively rare, with a frequency of approximately 1 in every 1000–3000 of the general population, the significantly increased breast cancer risk associated with these variants suggests that ATRIP can be regarded as a moderately to highly penetrant gene in the context of hereditary breast cancer. Here, ATRIP is linked to breast carcinoma.